Abstract
A promising strategy for cancer treatment is adoptive gene therapy / immunotherapy by genetically modifying T lymphocytes with a chimeric receptor (ch-TCR) so that cytotoxic T lymphocytes (CTL) can target and lyse tumors in a MHC-non-restricted manner. It is, however, not clear whether non-MHC-restricted tumor cell recognition by T cells will result in activation- induced apoptosis (AICD). This review discusses the factors that affect the development of AICD or CTL proliferation, and how such factors should be considered in the design of clinical trials using ch-TCR.
Keywords: Antigen-Specific Receptors, Cancer Adoptive Immunotherapy/, anti-CD3, TCR signaling
Current Gene Therapy
Title: Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy
Volume: 1 Issue: 3
Author(s): L. Ren-Heidenreich and L. G. Lum
Affiliation:
Keywords: Antigen-Specific Receptors, Cancer Adoptive Immunotherapy/, anti-CD3, TCR signaling
Abstract: A promising strategy for cancer treatment is adoptive gene therapy / immunotherapy by genetically modifying T lymphocytes with a chimeric receptor (ch-TCR) so that cytotoxic T lymphocytes (CTL) can target and lyse tumors in a MHC-non-restricted manner. It is, however, not clear whether non-MHC-restricted tumor cell recognition by T cells will result in activation- induced apoptosis (AICD). This review discusses the factors that affect the development of AICD or CTL proliferation, and how such factors should be considered in the design of clinical trials using ch-TCR.
Export Options
About this article
Cite this article as:
Ren-Heidenreich L. and Lum G. L., Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy, Current Gene Therapy 2001; 1 (3) . https://dx.doi.org/10.2174/1566523013348607
DOI https://dx.doi.org/10.2174/1566523013348607 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Structurally Diversified Synthesized Molecules as Monoacylglycerol Lipase Inhibitors and their Therapeutic uses
Current Drug Research Reviews The Role of Plant Lectins in the Cellular and Molecular Processes of Skin Wound Repair: An Overview
Current Pharmaceutical Design VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Controlled Somatic and Germline Copy Number Variation in the Mouse Model
Current Genomics Development of a Novel Pomegranate Polysaccharide Nanoemulsion Formulation with Anti-Inflammatory, Antioxidant, and Antitumor Properties
Current Drug Delivery Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics The Prognosis of Patients with Liver Metastases from Colorectal Cancer still Depends on Anatomical Presentation more than on Treatments
Current Cancer Drug Targets Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer
Current Protein & Peptide Science CENPA a Genomic Marker for Centromere Activity and Human Diseases
Current Genomics The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms
Anti-Cancer Agents in Medicinal Chemistry Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Bevacizumab Allows Preservation of Liver Function and its Regenerative Capacity after Major Hepatectomy
Anti-Cancer Agents in Medicinal Chemistry Crocin Suppresses Colorectal Cancer Cell Proliferation by Regulating miR-143/145 and KRAS/RREB1 Pathways
Anti-Cancer Agents in Medicinal Chemistry Beyond Cox-Inhibition: ‘Side-Effects’ of Ibuprofen on Neoplastic Development and Progression
Current Pharmaceutical Design Azo Reductase- Activated Colon- Targeting Prodrugs of Aminosalicylates for Inflammatory Bowel Disease: Preparation, Pharmacokinetic and Pharmacodynamic Profile
Inflammation & Allergy - Drug Targets (Discontinued) Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design